<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="39908">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02586857</url>
  </required_header>
  <id_info>
    <org_study_id>ACE-ST-209</org_study_id>
    <nct_id>NCT02586857</nct_id>
  </id_info>
  <brief_title>A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)</brief_title>
  <official_title>A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Acerta Pharma BV</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Acerta Pharma BV</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 1b/2, multicenter, open-label study designed to evaluate the efficacy and safety of
      ACP-196 in subjects with recurrent GBM who have progressed after 1 or 2 prior systemic
      treatment regimens.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary safety outcome measure includes type, frequency, severity, timing of onset, duration, and relationship to study drug of any TEAEs or abnormalities of laboratory tests, SAEs, DLTs, or AEs leading to discontinuation of study treatment.</measure>
    <time_frame>13 cycles (each cycle is 28 days)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The primary efficacy outcome measure is overall response rate (ORR) per the Response Assessment in Neuro-oncology (RANO) criteria assessed by investigator.</measure>
    <time_frame>13 cycles (each cycle is 28 days)</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Glioblastoma Multiforme</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ACP-196 200mg administered PO BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ACP-196 400mg administered PO QD</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACP-196</intervention_name>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed GBM at first or second recurrence after concurrent or
             adjuvant chemotherapy or radiotherapy (must have received temozolomide).

          -  Radiographic demonstration of disease progression by MRI following prior therapy.

          -  ECOG performance status ≤ 2.

          -  Life expectancy ≥ 12 weeks.

          -  Completion of all prior anticancer therapy before first ACP-196 dose.

        Exclusion Criteria:

          -  Three or more prior lines of systemic therapy for GBM.

          -  Significant cardiovascular disease.

          -  Evidence of bleeding diathesis or coagulopathy.

          -  Requires urgent palliative intervention for primary disease.

          -  History of stroke or clinically significant intracranial hemorrhage within 6 months
             before first dose of study drug.

          -  Breastfeeding or pregnant.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Christine Hegi, CTM</last_name>
    <phone>403-262-7176</phone>
    <email>c.hegi@acerta-pharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ron Weitzman, MD</last_name>
    <phone>650-542-7744</phone>
    <phone_ext>323</phone_ext>
    <email>ron.weitzman@acerta-pharma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <lastchanged_date>November 29, 2016</lastchanged_date>
  <firstreceived_date>October 17, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Glioblastoma Multiforme</keyword>
  <keyword>GBM</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
